ADCendo ApS

Adcendo ApS is a clinical-stage biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Spun out of the Finsen Laboratory at Rigshospitalet and the University of Copenhagen, the company is advancing a pipeline including ADCE-D01 (uPARAP) in soft tissue sarcoma and ADCE-T02 (Tissue Factor) in solid tumors.